gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Lymphocyte antigen 9

Ly9, CD229
LY9 belongs to the SLAM family of immunomodulatory receptors (see SLAMF1; MIM 603492) and interacts with the adaptor molecule SAP (SH2D1A; MIM 300490) (Graham et al., 2006 [PubMed 16365421]).[supplied by OMIM, Mar 2008] (from NCBI)
Top mentioned proteins: SLAM, CD84, CD48, SAP, CD2
Papers on Ly9
Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses.
Engel et al., Barcelona, Spain. In J Immunol, Feb 2016
Ly9 (CD229, SLAMF3), a member of the signaling lymphocytic activation molecule family receptors, has been implicated in the development and function of innate T lymphocytes.
Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
EuroFlow group et al., Salamanca, Spain. In Cytometry B Clin Cytom, Jan 2016
Here we compared the utility of CD229, CD54, and CD319 for the identification of normal and aberrant PCs.
Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
Omedè et al., Torino, Italy. In Cytometry B Clin Cytom, Jan 2016
Based on the antigens expression and monoclonal antibody availability, CD150, CD48, CD229, CD352, CD319, CD272, CD86, CD200 and CD184 were subsequently tested in 24 NDMM, 8 relapsed MM (RMM), 6 plasma cell leukemia (PCL) and 13 healthy subjects.
Signaling Lymphocytic Activation Molecule Family Receptor Homologs in New World Monkey Cytomegaloviruses.
Angulo et al., Barcelona, Spain. In J Virol, Dec 2015
Furthermore, the OMCMV genome encodes A33, an LY9 (SLAMF3) homolog, and A43, a CD48 (SLAMF2) homolog, two soluble glycoproteins which recognize their respective cellular counterreceptors and thus are likely to be viral SLAMF decoy receptors.
A polymorphism in a phosphotyrosine signalling motif of CD229 (Ly9, SLAMF3) alters SH2 domain binding and T-cell activation.
Brown et al., Oxford, United Kingdom. In Immunology, Nov 2015
Here we show that the Val602 variant of the non-synonymous single nucleotide polymorphism (SNP) rs509749 in the SLAM family member CD229 (Ly9, SLAMF3) has a two-fold lower affinity compared with the SLE-associated Met602 variant for the small adaptor protein SAP.
Osteoblast ablation reduces normal long-term hematopoietic stem cell self-renewal but accelerates leukemia development.
Bhatia et al., Duarte, United States. In Blood, May 2015
OB ablation resulted in increase in cells with a LSK Flt3(-)CD150(+)CD48(-) long-term HSC (LTHSC) phenotype but reduction of a more highly selected LSK Flt3(-)CD34(-)CD49b(-)CD229(-) LTHSC subpopulation.
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.
Atanackovic et al., Salt Lake City, United States. In Hum Vaccin Immunother, 2014
We recently described surface molecule CD229 as a potential therapeutic target for MM.
The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection.
Bouhlal et al., Amiens, France. In Plos One, 2013
We recently characterized for the first time the expression of Signaling Lymphocyte Activating Molecule 3 (SLAMF3) in human hepatocytes and here, we report that SLAMF3 interacts with the HCV viral protein E2 and is implicated in HCV entry process.
SLAM family markers resolve functionally distinct subpopulations of hematopoietic stem cells and multipotent progenitors.
Morrison et al., Dallas, United States. In Cell Stem Cell, 2013
Here we show that four SLAM family markers, CD150, CD48, CD229, and CD244, can distinguish HSCs and MPPs from restricted progenitors and subdivide them into a hierarchy of functionally distinct subpopulations with stepwise changes in cell-cycle status, self-renewal, and reconstituting potential.
Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression.
Bouhlal et al., Amiens, France. In Plos One, 2012
In the present study, we demonstrate for the first time that hepatocytes express signalling lymphocytic activation molecule family member 3 (SLAMF3/CD229) but not other SLAMF members.
Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation.
Tsokos et al., Boston, United States. In J Immunol, 2012
SLAMF3 and SLAMF6 T cell surface expression and IL-17 levels significantly correlate with disease activity in systemic lupus erythematosus patients
Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma.
Kröger et al., Hamburg, Germany. In Haematologica, 2011
CD229 is specifically over-expressed on myeloma cells including their clonogenic precursors and contributes to their malignant phenotype.
Susceptibility loci for the defective foreign protein-induced tolerance in New Zealand Black mice: implication of epistatic effects of Fcgr2b and Slam family genes.
Nishimura et al., Yokohama, Japan. In Eur J Immunol, 2011
Data show that defective tolerance was observed only in Fcgr2b-deficient mice with autoimmune-type Slam family genes, indicating that epistatic effects of both genes are involved.
The role of SLAM/CD2 polymorphisms in systemic autoimmunity.
Wakeland et al., Dallas, United States. In Curr Opin Immunol, 2010
Three members of this gene family, Ly108, Ly9, and CD84, exhibit polymorphisms that strongly influence susceptibility to systemic autoimmunity, notably in mice, but also in some human populations.
SLAM family receptors and SAP adaptors in immunity.
Schwartzberg et al., Bethesda, United States. In Annu Rev Immunol, 2010
The signaling lymphocyte activation molecule (SLAM)-associated protein, SAP, was first identified as the protein affected in most cases of X-linked lymphoproliferative (XLP) syndrome, a rare genetic disorder characterized by abnormal responses to Epstein-Barr virus infection, lymphoproliferative syndromes, and dysgammaglobulinemia. SAP consists almost entirely of a single SH2 protein domain that interacts with the cytoplasmic tail of SLAM and related receptors, including 2B4, Ly108, CD84, Ly9, and potentially CRACC.
Association of LY9 in UK and Canadian SLE families.
CaNIOS GenES Investigators et al., London, United Kingdom. In Genes Immun, 2008
A family-based association study in the United Kingdom and Canada identifies genetic variants in the LY9 promoter and coding region contributing to systemic lupus erythematosus susceptibility.
Characterization of mouse CD229 (Ly9), a leukocyte cell surface molecule of the CD150 (SLAM) family.
Engel et al., Barcelona, Spain. In Tissue Antigens, 2007
CD229 is a pan-lymphocyte marker and indicate that mAbs against CD229 are able to down-modulate T-cell activation.
Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules.
Tangye et al., Australia. In Annu Rev Immunol, 2006
During the past eight years, it has been established that the SLAM family of cell surface receptors (SLAM, 2B4, NTB-A, Ly9, CD84) and the SAP family of adaptors (SAP, EAT-2, ERT) play critical roles in lymphocyte development, differentiation, and acquisition of effector functions.
Molecular and cellular pathogenesis of X-linked lymphoproliferative disease.
Tangye et al., Philadelphia, United States. In Immunol Rev, 2005
SAP is expressed in T cells, natural killer (NK) cells, and NKT cells, where it binds to the cytoplasmic domain of the surface receptor SLAM (CD150) and the related receptors, 2B4 (CD244), CD84, Ly9 (CD229), NK-T-B-antigen, and CD2-like receptor-activating cytotoxic T cells.
2B4: an NK cell activating receptor with unique specificity and signal transduction mechanism.
Colonna et al., Basel, Switzerland. In Hum Immunol, 2000
2B4 is a cell surface glycoprotein of the Ig-superfamily structurally related to CD2-like molecules such as CD2, CD48, CD58, CD84, Ly-9, and SLAM.
share on facebooktweetadd +1mail to friends